SCHEMBL24975149

SCHEMBL24975149

CCCN(C(C)=O)c1ccc(-c2ccc(C(=O)NCc3cccnc3)cn2)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 4/20 0.51
▸ TSHR P16473 1/20 0.47
▸ LMNA P02545 3/20 0.46
▸ EIF4E P06730 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ TRPV1 Q8NER1 1/20 0.46
▸ HPGDS O60760 1/20 0.45
▸ HTT P42858 4/20 0.45
▸ ALDH1A1 P00352 3/20 0.45
▸ GFER P55789 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ USP2 O75604 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ PSMD14 O00487 1/20 0.42
▸ STAMBP O95630 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29800935 1.00 NAMPT (0.51) NAMPTTSHRLMNAEIF4EMAPK1
SCHEMBL24975321 0.93 NAMPT (0.49) NAMPTTSHRLMNAEIF4EMAPK1
SCHEMBL29801142 0.93 NAMPT (0.49) NAMPTTSHRLMNAEIF4EMAPK1
SCHEMBL29801005 0.90 EIF4E (0.44) NAMPTTSHRLMNAEIF4EMAPK1
SCHEMBL24975150 0.90 EIF4E (0.44) NAMPTTSHRLMNAEIF4EMAPK1
SCHEMBL24976308 0.89 NAMPT (0.51) NAMPTLMNAEIF4EMAPK1HPGDS
SCHEMBL29801118 0.89 NAMPT (0.51) NAMPTLMNAEIF4EMAPK1HPGDS
SCHEMBL24975327 0.88 EIF4E (0.45) NAMPTTSHRLMNAEIF4EMAPK1
SCHEMBL29801044 0.88 EIF4E (0.45) NAMPTTSHRLMNAEIF4EMAPK1
SCHEMBL24975196 0.88 NAMPT (0.51) NAMPTLMNAEIF4EMAPK1HPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS REMEDY PLAN, INC. (US) 2023-01-26 — — US disclosed
CN-114929672-A Cancer therapy targeting cancer stem cells 治疗方案股份有限公司 2022-08-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230023124-A1 CANCER TREATMENTS TARGETING CANCER STEM CELLS MCL1, KIT, GLI1 NAMPT 2789/4885TSHR 3673/4885LMNA 2667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback